Please assess the completion status of the following clinical trial:

Trial Title: ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects age 18 and older.~2. Subject (or Legal Guardian if applicable) is willing and able to provide consent before any study-specific test or procedure is performed, signs the consent form, and agrees to attend all required follow-up visits. NOTE: For subjects less than 20 years of age enrolled at a Japanese center, the subject's legal representative, as well as the subject, must provide written informed consent.~3. Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3 or 4.~4. Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA:~   * Degree of stenosis ≥ 70% by visual angiographic assessment~  * Vessel diameter ≥ 4 and ≤ 6 mm~  * Total lesion length (or series of lesions) ≥ 30 mm and ≤ 140 mm (Note: Lesion segment(s) must be fully covered with one ELUVIA stent or up to two Zilver PTX stents)~  * Long Lesion Substudy: Total lesion length (or series of lesions) \>140 mm and ≤ 190 mm (Note: Lesion segment(s) will require overlapping of two ELUVIA stents).~  * For occlusive lesions requiring use of re-entry device, lesion length ≤ 120 mm~  * Long Lesion Substudy: For occlusive lesions requiring use of re-entry device, lesion length \> 120 mm and ≤ 170 mm~  * Target lesion located at least three centimeters above the inferior edge of the femur~5. Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (\<50% stenosis) to the ankle or foot with no planned intervention.~Exclusion Criteria:~1. Previously stented target lesion/vessel.~2. Target lesion/vessel previously treated with drug-coated balloon \<12 months prior to randomization/enrollment.~3. Subjects who have undergone prior surgery of the SFA/PPA in the target limb to treat atherosclerotic disease.~4. Use of atherectomy, laser or other debulking devices in the target limb SFA/PPA during the index procedure.~5. History of major amputation in the target limb.~6. Documented life expectancy less than 24 months due to other medical co-morbid condition(s) that could limit the subject's ability to participate in the clinical trial, limit the subject's compliance with the follow-up requirements, or impact the scientific integrity of the clinical trial.~7. Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated.~8. Known hypersensitivity/allergy to the investigational stent system or protocol related therapies (e.g., nitinol, paclitaxel, or structurally related compounds, polymer or individual components, and antiplatelet, anticoagulant, thrombolytic medications).~9. Platelet count \<80,000 mm3 or \>600,000 mm3 or history of bleeding diathesis.~10. Concomitant renal failure with a serum creatinine \>2.0 mg/dL.~11. Receiving dialysis or immunosuppressant therapy.~12. History of myocardial infarction (MI) or stroke/cerebrovascular accident (CVA) within 6 months prior to randomization/enrollment.~13. Unstable angina pectoris at the time of randomization/enrollment.~14. Pregnant, breast feeding, or plan to become pregnant in the next 5 years.~15. Current participation in another investigational drug or device clinical study that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current study endpoints (Note: studies requiring extended follow-up for products that were investigational, but have become commercially available since then are not considered investigational studies).~16. Septicemia at the time of randomization/enrollment.~17. Presence of other hemodynamically significant outflow lesions in the target limb requiring intervention within 30 days of randomization/enrollment.~18. Presence of aneurysm in the target vessel.~19. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to randomization/enrollment.~20. Perforated vessel as evidenced by extravasation of contrast media prior to randomization/enrollment.~21. Heavily calcified lesions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELUVIA Stent Implantation (Type: EXPERIMENTAL): Percutaneous stent placement in the SFA/PPA
- Zilver PTX Stent Implantation (Type: ACTIVE_COMPARATOR): Percutaneous stent placement in the SFA/PPA

Based on this trial design, predict the completion outcome and termination type (if applicable).